The addition of oxaliplatin to the Mayo Clinic schedule significantly increases its toxicity: a retrospective analysis of patients with advanced colorectal cancer

• Autores: Regina Gironés Sarrió, Pedro López Tendero, Angel Agustín Segura Huerta, Eva Calabuig Muñoz, Ana Lucía Yuste Izquierdo, Jorge Aparicio Urtasun
• Localización: Revista de oncología: Publicación oficial de la Federación de Sociedades Españolas de Oncología y del Instituto Nacional de Cancerología de México, ISSN 1575-3018, Vol. 5, Nº. 2, 2003, págs. 88-92
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background. Oxaliplatin has been introduced to the clinical setting in combination with 5-fluorouracil/folinic acid (5-FU/FA) in an attempt to improve the response rate against colorectal cancer. It is unclear the optimum schedule of combination. In order to evaluate the response rate and toxicity profile of the combination of oxaliplatin with 5-FU/FA, according to the Mayo Clinic schedule, we evaluated our patients in a retrospective analysis.

    Methods. Eighteen patients with advanced colorectal cancer were treated between June 2000 and October 2001. Sixty-seven percent were males, and median age was 58 years (range, 33-70). Two thirds of them had been previously treated with chemotherapy for advanced disease.

    Results. A total of 80 cycles have been administered, with a median of 5 per patient (range, 1-9). The response rate was 33%, and median overall survival was 16 months since the first cycle administration. Grade 3 and 4 toxic effects appeared in 33% of patients, mainly diarrhea and mucositis. Dose reductions were needed in 61%.

    Conclusion. Oxaliplatin combined with 5-FU/FA according to the Mayo Clinic schedule is significantly toxic. We recommend dose reduction of 5-FU in this treatment schedule.